Feb 25, 2026 08:20AM
Feb 23, 2026 04:05PM
Oct 29, 2025 09:01AM
Oct 29, 2025 09:00AM
Oct 28, 2025 09:23AM
Oct 28, 2025 08:43AM
Aug 26, 2025 06:35AM Oppenheimer Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN)
Jul 15, 2025 06:15AM
Jun 25, 2025 10:03AM
Apr 10, 2025 05:32AM
Sep 21, 2023 10:00AM
Sep 15, 2023 09:29AM
Sep 15, 2023 09:29AM
Jun 22, 2023 08:00AM BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (I
Apr 26, 2023 04:03PM
Mar 14, 2023 08:00AM
Mar 7, 2023 04:08PM
Mar 7, 2023 04:05PM
Mar 7, 2023 07:07AM
Mar 6, 2023 07:28PM
Feb 27, 2023 04:03PM BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
Jan 9, 2023 05:05AM
Jan 8, 2023 11:00AM
Jan 4, 2023 08:39AM
Nov 7, 2022 04:31PM
Nov 7, 2022 04:30PM
Oct 26, 2022 04:03PM
Oct 12, 2022 05:12PM After-Hours Movers: DWAC Up as Truth Approved for Google Play, AMAT Falls on Lower Outlook
Oct 12, 2022 04:05PM
Oct 12, 2022 04:05PM
Feb 9, 2022 08:31AM
Feb 9, 2022 08:31AM
Oct 28, 2021 06:20AM
Oct 27, 2021 04:05PM
Aug 27, 2021 09:51AM European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Aug 27, 2021 09:02AM
Aug 27, 2021 09:01AM
Aug 24, 2021 07:20AM
Jul 28, 2021 04:03PM
Jun 25, 2021 07:30AM
Jun 25, 2021 07:29AM
Jun 22, 2021 07:15AM BioMarin Pharmaceutical Inc. (BMRN) Risk Reward Looks Very Attractive Ahead of Voxzogo Launch - BofA Securities
Apr 29, 2021 04:03PM
Apr 15, 2021 08:35AM
Apr 15, 2021 08:31AM
Mar 20, 2021 11:15AM
Mar 3, 2021 08:32AM
Mar 3, 2021 08:31AM
Feb 25, 2021 04:05PM BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
Dec 21, 2020 08:38AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All